A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (May 2021)
David Clark, John Sheppard, and Todd C. Brady